ESR1 and breast cancer: If such a procedure worked, one would expect to see the intrinsic signature of luminal breast cancer subtype emerging as downstream to gene ER. Furthermore, one could identify driver mutations of the mesenchymal/basal subtype for which therapeutic strategies fail to work.